Cost-effectiveness modelling is essential to support decision making relating to screening in vaccinated populations. HPV-FRAME will provide reporting requirements for HPV modelling studies.
Additions to the HPV FRAME reporting requirements for screening in vaccinated populations will be presented. Key issues are data sources presently used for integrated vaccination-screening strategies (randomized screening trials in vaccinated women, screening trials and cohort studies with HPV genotyping, and screening and vaccination registries), calibration targets, screening of cohorts offered first or second generation vaccines, vaccination and screening uptake, and risk based screening.
In the coming years, vaccinated women will become screen-eligible and a timely cost effectiveness assessment is important when preparing an integrated vaccination-and-screening programme. An itemized reporting checklist for modelling studies will provide guidance and support good modelling practice.